TNF Inhibitor denied as non-formulary by OptumRx?

Adalimumab biosimilar preferred (Cyltezo / Hyrimoz / Adalimumab-adaz). Step therapy from biosimilar. Self-administered — Part D / pharmacy benefit.

OptumRx Continuity of Care provisions for >180-day stable patients. ACR 2019 anti-non-medical-switching position. State step-therapy override laws (NY §4903, TX SB 1216, CA HSC §1367.241).

## Why OptumRx Denied Your TNF Inhibitor as Non-Formulary

OptumRx manages a tiered formulary that lists which drugs are covered at preferred cost-sharing levels. A non-formulary denial means the specific TNF inhibitor your prescriber selected is not on OptumRx's current formulary — or is placed on an excluded or non-preferred tier — while one or more other biologics may occupy a preferred position. OptumRx's formulary is updated periodically, so a drug that was covered last year may no longer be preferred.

## Why This Denial Is Frequently Overturned

Formulary exclusions are not absolute. Most plans, including those administered by OptumRx, maintain a formulary exception process that allows coverage of a non-formulary drug when a preferred alternative is clinically inappropriate for a specific patient. TNF inhibitors, while sharing a mechanism, are not clinically interchangeable for every patient — differences in labeled indications, administration route, and individual patient history can make a non-preferred agent the only medically appropriate choice. A well-documented exception request citing these clinical reasons has a meaningful chance of approval.

## Federal Appeal Rights

Under ACA §2719 and applicable state external-review laws, a formulary exception denial is an adverse benefit determination subject to both internal and external appeal. Under ERISA §503, the plan must disclose the specific formulary criteria it applied and provide its complete file. If the plan offers no formulary exception process, or if your exception request is denied, you may proceed to external review — typically within 4 months of the denial. Expedited review (72 hours) is available for urgent clinical situations.

## Concrete Appeal Steps and Timeline

1. Confirm whether OptumRx has a formulary exception process — it is usually described in your Summary Plan Description or Evidence of Coverage document. 2. Submit a formulary exception request (this is a formal appeal right, not a courtesy process) along with your prescriber's clinical justification. 3. If the exception is denied, file a Level 1 internal appeal within the timeframe shown on your denial letter. 4. If internal appeal fails, request independent external review before the 4-month window closes.

## Documentation to Gather

• Diagnosis and indication: Chart documentation confirming the diagnosis for which the TNF inhibitor was prescribed, matching it to the drug's FDA-labeled indication.
• Formulary alternative contraindication or failure: If a preferred formulary alternative exists, document in the chart — with dates and clinical outcomes — why each preferred alternative was tried and failed, could not be tolerated, or is contraindicated for this patient.
• Prescriber letter of medical necessity: A letter from your physician explaining why the specific non-formulary TNF inhibitor is required, what makes the formulary alternatives inappropriate, and citing the applicable professional society guideline organization.
• Current prescribing label: Confirm the drug's labeled indications and any clinically relevant differences from the preferred formulary agent.

## Criteria-Mapping Structure

Request the text of OptumRx's formulary exception criteria from the plan documents or the denial letter. For each exception criterion listed — typically "preferred alternative is contraindicated," "preferred alternative caused adverse reaction," or "preferred alternative was tried and failed" — provide the corresponding chart documentation by date and source. A direct criterion-to-evidence mapping in your appeal letter is the clearest way to demonstrate that the exception standard is met and minimizes the risk of a second denial on procedural grounds.